1Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1 )-cells[J]. J Endocrinol,2002,174(2) : 233-246.
2Lewis JT, Dayanandan B, Habener JF, et al. Glucose-depentent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist [J].Endocrinology, 2000,141 (10) :3710-3716.
3Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity [J]. Nat Med, 2002,8(3) :738-742.
4Hinke SA, Gelling RW, Pederson RA, et al. Dipeptidyl peptidaseⅣ-resistant [ D-Ala(2) ] glucose- dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats[J]. Diabetes, 2002,51 (3) :652-661.
5Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes [J]. Diabetes Care, 2003,26 (10) :2929-2940.
6Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a GLP-l-albumin conjugate which retains the ability to activate the GLP-I receptor in vivo [J]. Diabetes, 2003,52 (3) : 751-759.
7Wang Q, Brubaker PL. Glucagon-like peptide-I treatment delays the onset of diabetes in 8 week-old db/db mice [J]. Diabetologia, 2002,45 (10) : 1263-1273.
8Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagons-like peptide-1 in obese type 2 diabetic patients and healthy subjects[J]. J Clin Endocrinol Metab, 2003,88(2):220-224.
9Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagons-like peptide-1 (7-36) amide on adlibitum energy intakein humans[J]. J Clin Endocrinol Metab , 2001,86(9):4382-4389.
10Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagons-like peptide 1 on glycaemic control, insulin sensitivity,and beta-cell function in type 2 diabetes: a parallel-group study [J].Lancet, 2002,359 (4) :824-830.
